NCT01042379 2026-03-13
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
Clinical Trials
19 trialsNCT04947254 2026-02-19
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05601440 2026-02-11
Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT05718323 2026-02-06
RAISE
ETOP IBCSG Partners Foundation
Phase 2 Recruiting
NCT05700721 2026-02-05
Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05526989 2025-12-04
Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT06180356 2025-11-28
ANALLISA
MedSIR
Phase 2 Recruiting
NCT04641247 2025-09-29
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
GlaxoSmithKline
Phase 2 Recruiting
NCT06747845 2025-09-16
ParpVax2
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
NCT04341181 2025-07-25
ProTarget
Rigshospitalet, Denmark
Phase 2 Recruiting
NCT06212583 2025-05-01
KNIGHTS
University of Maryland, Baltimore
Phase 2 Recruiting
NCT05990192 2025-04-22
SOPRANO
Institute of Cancer Research, United Kingdom
Phase 2 Recruiting
NCT04423185 2025-02-11
PLATFORM Study of Precision Medicine for Rare Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT04812366 2024-12-16
GUNS
University of British Columbia
Phase 2 Recruiting
NCT05183984 2024-10-16
NIRVANA-1
ARCAGY/ GINECO GROUP
Phase 2 Recruiting
NCT04817956 2024-02-29
IMPRESS-N
Oslo University Hospital
Phase 2 Recruiting
NCT05961124 2023-11-22
Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer
Sunnybrook Health Sciences Centre
Phase 2 Recruiting
NCT06141265 2023-11-21
BRAND
Peking University Cancer Hospital & Institute
Phase 2 Recruiting
NCT04681469 2022-08-04
PRIME
Gruppo Oncologico del Nord-Ovest
Phase 2 Recruiting